For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

Halozyme Therapeutics, Inc. (HALO) reported first-quarter 2024 adjusted earnings of 79 cents per share, which surpassed the Zacks Consensus Estimate of 69 cents. The company had recorded earnings of 47 cents per share in the year-ago period.Total revenues increased 21% year over year to $195.9 million in the first quarter. The top line was driven by higher royalty payments from J&J (JNJ) for subcutaneous Darzalex (daratumumab) and Roche (RHHBY) for Phesgo, as well as increased milestone payments from collab ...

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: The Citizens JMP Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, May 14, 2024 Presentation Time: 7:00 a.m. PT / 10:00 a.m. ET Location: New York, NY   Event: Benchmark 202 ...

财务数据和关键指标变化 - 第一季度收入增长21%至1.959亿美元,主要归功于Wave 2产品DARZALEX FASPRO和Phesgo的持续势头 [47] - 第一季度EBITDA增长56%至1.157亿美元,主要由于收入增长和运营费用相对平稳 [50] - 第一季度GAAP每股收益为0.60美元,非GAAP每股收益为0.79美元,去年同期分别为0.29美元和0.47美元 [51][52] 各条业务线数据和关键指标变化 - DARZALEX FASPRO第一季度销售额增长21%至27亿美元,主要得益于全线治疗领域的市场份额增长 [23] - Phesgo第一季度销售额增长70%至3.88亿瑞士法郎,美国转换率达25%,全球转换率达41% [25] - VYVGART Hytrulo 2023年销售额达12亿美元,正在扩大获批适应症和覆盖范围 [27] 各个市场数据和关键指标变化 - DARZALEX FASPRO在美国渗透率超过90%,在美国以外地区预计超过80% [23] - Phesgo在美国的转换率达25%,全球转换率达41%,Roche预计未来转换率将达到50% [25] - VYVGART Hytrulo在美国和欧洲获批治疗全身性重症肌无力,在日本获批并允许患者自我注射 [27] 公司战略和发展方向及行业竞争 - 公司有望在2027年实现10亿美元的版税收入目标,主要得益于Wave 2和Wave 3产品的强劲表现 [22] - 公司正在积极与多家制药和生物技术公司就ENHANZE和高容量自动注射器展开合作洽谈,并已有多家公司进入条款讨论阶段 [61][62][94] - 公司正在投资开发更高产出的ENHANZE原料药,以降低合作伙伴的成本,应对2027年专利到期后的市场竞争 [127][129] 管理层对经营环境和未来前景的评论 - 公司对2024年全年财务指引保持信心,预计总收入增长10%-19%,EBITDA增长26%-37%,非GAAP每股收益增长28%-41% [15] - 管理层对ENHANZE技术在自身免疫、中枢神经系统和肿瘤领域的应用前景充满信心,认为其安全性记录和全球监管批准历史为其带来优势 [62][63] - 管理层认为高容量自动注射器是一项突破性技术,正在与多家潜在合作伙伴进行评估和洽谈 [94][95] 问答环节重要的提问和回答 问题1 **Vikram Purohit提问** 询问公司新的ENHANZE和高容量自动注射器合作的进展情况 [61] **Helen Torley回答** - 公司正在与10多家制药和生物技术公司就ENHANZE展开深入讨论,多家公司已进入条款讨论阶段 [62][63] - 公司高容量自动注射器引起了广泛兴趣,多家公司正在评估设备性能,公司也在与现有和潜在合作伙伴就开发计划和商业化进行讨论 [94][95] 问题2 **Jessica Fye提问** 询问新的ENHANZE和自动注射器合作的具体情况,是否会有不同的经济条款 [72][73] **Helen Torley回答** - 公司正在就ENHANZE单独、ENHANZE+自动注射器以及自动注射器单独的合作进行洽谈 [74] - 新合作的经济条款可能会有所不同,取决于是否为独家或非独家授权,以及产品的开发阶段 [75] 问题3 **Michael DiFiore提问** 询问Phesgo面临Perjeta生物类似药竞争的影响,以及subcu Nivo和subcu Tecentriq的适应症覆盖情况 [79][84] **Helen Torley回答** - 公司认为Phesgo的转换率有望超过50%,类似于Herceptin subcu的情况,不会受Perjeta生物类似药的太大影响 [80][81] - subcu Nivo预计将覆盖75%的IV适应症,主要由于与CTLA4-Ig联用的适应症未经研究 [84]

For the quarter ended March 2024, Halozyme Therapeutics (HALO) reported revenue of $195.88 million, up 20.8% over the same period last year. EPS came in at $0.79, compared to $0.47 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $201.72 million, representing a surprise of -2.90%. The company delivered an EPS surprise of +14.49%, with the consensus EPS estimate being $0.69.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.49%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.82 per share when it actually produced earnings of $0.82, delivering no surprise.Over the last four quarter ...

Halozyme Therapeutics, Inc. First Quarter 2024 Financial & Operating Results NASDAQ: HALO May 7, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 _______________________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million, Representing YOY Growth of 10% - 19%, Adjusted EBITDA of $535 - $585 million, Representing YOY Growth of 26% - 37% and Non-GAAP Diluted EPS of ...